Abcon Therapeutics is developing an antibody-drug conjugate (ADC) that targets the CD6 cell surface protein on T-cells. In pathogenic conditions, such as T-cell lymphoma and inflammatory conditions, the ADC binds to all T-cells, but the drug (toxin) only affects activated dividing T-cells (i.e. the cancerous ones in T-Cell Lymphoma) so these are killed, and normal inactive T-cells are spared. CD6 is found exclusively on T-cells; thus, the ADC specificity is very good. The Company plans to develop a pipeline of ADCs targeting different types of cancer.